

Attracting top manages	02	BIO 2006	04	ACPGF investment success	06
Design award for Micronix	02	SA bioscience five years on	04	Biotech careers	07
Clinical trials for cancer compound	03	MAbSA Technologies	05	People on the move	07
vivoPharm expands preclinical services	03	Flinders Profit from IP Program	06	In brief	08
				Coming events	08

## Pan-Pacific partnership for TGR

TGR BioSciences Pty Ltd has secured a long term licensing agreement with PerkinElmer, Inc., a leading US technology company, providing worldwide distribution of TGR's new generation of drug screening kits.



Dr Leanna Read, Managing Director of TGR Biosciences Pty Ltd

The SureFire™ ERK assay kits use cutting-edge technology to help pharmaceutical and biotechnology companies as well as research institutions to identify new drugs effective against cancer, asthma, heart disease and other conditions.

"We already sell our kits to major pharmaceutical and biotechnology companies in the US, Europe and the UK," said Dr Leanna Read, Managing Director of TGR.

"PerkinElmer's extensive global marketing networks and resources will ensure much greater market penetration worldwide, increasing our sales and our growth as a successful biotechnology company."

The kits work by detecting changes in proteins in cells. Finding such changes can be used as the basis to develop new treatments for a number of diseases.

Combined with PerkinElmer's AlphaScreen® technology, the kits offer precision, accuracy and speed. The screening process can also be fully automated: thousands of samples can be tested in a day.

"Our technology is world-leading. Our assay kits offer significant technical advantages and are more cost-effective to use than competing products," said Dr Read.

"Our distribution partnership with PerkinElmer validates the commercial, as well as scientific merit of TGR's SureFire™ technology and makes it more readily available to customers worldwide engaged in basic research and drug discovery."

"Combining our highly sensitive AlphaScreen® technology with TGR's SureFire™ cellular ERK assay takes drug screening to a previously unrealised level", said Ken King, vice president and general manager, Molecular Medicine, for PerkinElmer's Life and Analytical Sciences division.

"The addition of the AlphaScreen® SureFire™ ERK assay expands PerkinElmer's robust offering in the field of cell-based functional drug screening and furthers our commitment to build the most innovative tools for today's high throughput screening (HTS) labs."

**For more information on TGR Biosciences visit [www.tgr-biosciences.com.au](http://www.tgr-biosciences.com.au)**

## Going global attracts top managers

Heike Wolff has 24 years experience recruiting top managers for some of the world's leading bioscience and pharmaceutical companies.



Ms Heike Wolff

In May, she came to Australia - by invitation of Bio Innovation SA - to find out how bioscience companies here could benefit by recruiting top management talent from overseas. "Australia needs to think global" she said. "If companies here were to recruit the best managers from Europe, they would become internationally focussed."

It is not, however, just a question of Australian companies being more ambitious in their search. She believes that the perception and presentation of Australia overseas needs to change in order to give an accurate picture of the opportunities on offer.

As part of her research, Ms Wolff identified that Europeans regard Australia as a welcoming, open-minded country with an emphasis on lifestyle and a high standard of living.

Ms Wolff said, Australia's achievements in science and technology are not well publicised overseas and more could be done to communicate those success stories effectively. "You need contacts to communicate," said Ms Wolff. "You need a bridge between companies here and companies in Europe."

The government has an important role to play in bridging this gap. Offering professional help and advice via the internet and its diplomatic representatives overseas is one way to attract management talent.

Australian companies also need support for overseas marketing activities together with a media strategy that presents Australia as a dynamic, innovative country, publicising its scientific strengths.

But attracting the best managers from overseas is not just about presenting the successes and opportunities Australia has to offer, it is also knowing how to identify the right people.

"Top managers have flexibility, personality, social awareness and competence," said Ms Wolff. "They know their industry; they have leadership and conflict management skills. They are also entrepreneurial. This is very important, particularly for small companies."

Having a combination of scientific strength, business acumen and entrepreneurial thinking is essential but often hard to find in one person. Most managers exhibit one of the qualities, while the successful leadership of an ambitious bioscience company requires a CEO to have all three.

"I find the best people through international research, networking and contacts. I talk to people personally," said Ms Wolff.

"Sometimes my task is also to secure money, working between venture capital companies, managers and bioscience companies."

Whether venture capitalists are involved or not, the same qualities apply when recruiting the best talent for bioscience companies: strength in science, business and entrepreneurship, plus an international perspective.

"The best managers have looked to the US because they have big companies there," said Ms Wolff. "But I believe that the profile is changing. When you attract Europeans to Australia, they will stay. They will bring something to the business environment here, leading to growth and success overseas."

Heike Wolff's company, Wolff and Partner Executive Search, is expanding to Australia with a base soon to be established in Adelaide.

**For more information contact [info@bioinnovationsa.com.au](mailto:info@bioinnovationsa.com.au)**

## Micronix wins international design award

Adelaide medical device company Micronix has gained international recognition for the design of its catheter tracking device. The Cortrak™ system, which monitors the placement of feeding tubes in real time, was recently awarded a silver medal at the Medical Design Excellence Awards in New York.

Mr David MacInnes, CEO of Micronix said receiving the award was a real honour. "I'm delighted that our Cortrak™ technology has been recognised as a groundbreaking product in the worldwide medical products market," he said.



Mr David MacInnes, CEO of Micronix

The Cortrak™ system was nominated for the award by Chicago-based Viasys Medsystems, who began marketing and distributing the product in the United States twelve months ago.

"Since its launch, sales of Cortrak™ have gathered momentum and we've just received a new purchase order from Viasys MedSystems for additional units," Mr MacInnes said.

A second product, CathRite™, is expected to be launched later in 2006. Based on the same platform technology as Cortrak™, CathRite™ will aid the placement of central venous catheters.

**To contact Micronix, phone (+618) 8272 5444 or email [dmacinnis@micronix.com.au](mailto:dmacinnis@micronix.com.au)**

## Bionomics nominates cancer compound for clinical trials

Bionomics Ltd has nominated a compound for clinical trials, which targets the blood supply of cancer tumours.

It puts Bionomics on track to become a fully-fledged clinical stage development company: its target is to have two compounds in clinical trials by 2008.

"What drives value for biotechnology companies is having new drugs for very significant diseases and conditions with unmet clinical needs," said Dr Deborah Rathjen, Managing Director and CEO.

"Companies with compounds in clinical development have significant value."

The compound – BNC105 – is a new type of drug called a Vascular Disruption Agent (VDA). It acts to rapidly shut down the blood supply within a tumour, "starving" it of the oxygen and nutrients it needs to survive.

"The beauty of this particular system is that the drug does not have to reach the tumour cell to kill it," explained Dr Gabriel Kremmidiotis, Bionomics' Vice President of Cancer Research.

"You kill the blood capillary and millions of tumour cells that depend on that capillary for survival die as a result." Research has shown that the compound is highly selective – it leaves blood vessels outside tumours

intact – and more potent than other compounds – avoiding the need for higher doses and the risk of toxicity.

"I believe our compound will revolutionise this particular field," said Dr Kremmidiotis.

"Ninety percent of the families I know have been touched by cancer in some way. The problem with chemotherapy and radiotherapy is that there are side effects and they don't always offer a cure."

"This particular compound offers a huge leap forward in making those therapies more efficient." BNC105 has been developed using Bionomics' biological and chemical platforms.

The acquisition of Iliad Chemicals Pty Ltd last year enabled Bionomics to fast-track the compound's development and the receipt of \$3.7 million by way of an Australian Government Commercial Ready grant in April has brought the prospect of clinical trials forward by several years.

Bionomics also continues to capitalise on its epilepsy and multiple sclerosis programs.

"At the end of 2005, we reached an agreement with Labcorp – the second largest diagnostic company in the US – to out-license our two epilepsy diagnostic tests," said Dr Rathjen.

Bionomics owns three technology platforms: Angene® used to identify drug targets to treat cancer; IonX®, used to identify targets for the diagnosis and treatment of epilepsy and MultiCore®, a ground-breaking chemical technology that has the ability to make compounds work more effectively as drugs by accessing the core of molecules.

**For more information on Bionomics, visit [www.bionomics.com.au](http://www.bionomics.com.au)**

## vivoPharm expands preclinical services

vivoPharm Pty Ltd has formed a strategic alliance with TetraQ, a contract research organisation based in Queensland, to expand its range of preclinical drug development services.



Dr Ralf Brandt, Managing Director of vivoPharm Pty Ltd

vivoPharm – based in Adelaide – is an industrial one-stop shop for preclinical services with a rapidly growing customer base in Australia, as well as overseas in Europe and the US. It is strong in the area of toxicology and cancer drug testing.

TetraQ specialises in testing drugs for pain and disorders of the central nervous system. "We are very pleased to access TetraQ's expertise in the central nervous field," said Dr Ralf Brandt, vivoPharm's managing director and CEO. "The alliance allows us to fill a gap in our service line-up and widen our reach in business development terms."

The two organisations are also part of a collaborative research project that has just secured \$1.7m in Federal Government funding – under the Research-Industry Partnerships Program – to develop new tools for a drug development "toolkit".

The tools use non-invasive imaging technology to significantly improve

the testing of cancer drugs on orthotopic tumours (grown in target organs) instead of under the skin.

vivoPharm is also in the process of obtaining certification for Good Laboratory Practice (GLP) for its safety and toxicology department. "The implementation of non-invasive imaging technology will allow the drug testing process to become more streamlined," said Dr Brandt.

"Together with the TetraQ alliance and our impending GLP certification, we offer a package of integrated services. We are also working on ways to advance technology."

vivoPharm was established in Adelaide three years ago and now employs 17 staff.

**For more information on vivoPharm, visit [www.vivopharm.com.au](http://www.vivopharm.com.au)**

# Success at BIO 2006

BIO 2006 in Chicago provided an opportunity for South Australian participants to pursue leads and “get on the radar” of major international bioscience companies.

Adelaide Research and Innovation (ARI) Pty Ltd – the commercialisation arm of the University of Adelaide - and SARDI are close to signing deals after attending the annual event that attracts over 19,000 people from across the globe.

ARI hope to secure at least two major commercial research collaborations and two technology licences in addition to key partnerships for one of the university’s spin-out companies, Reproductive Health Sciences.

Professor Simon Maddocks, Chief Scientist of Livestock Systems at SARDI, used his attendance at BIO 2006 as an opportunity to pursue a deal that, once signed, promises to be “significant”.

Dr John Turner, the Managing Director of Flinders Technologies – the investment and commercialisation arm of Flinders University – used his first attendance at BIO to secure 12 meetings regarding the development of a new treatment for pancreatitis.

The project has recently attracted a \$50,000 Commercial Development Initiative grant from Bio Innovation SA.


“It was a very different cohort of people at BIO compared to other tradeshows and conferences that I’ve been to previously in the USA,” said Dr Turner.

“There were a lot of people presenting early-stage work. It was useful to see what the large corporations are looking for in terms of products, opportunities and deals.”

Major biotechnology and pharmaceutical companies showed a keen interest in early-stage research and commercialisation opportunities.

“The large companies are increasingly recognising universities as sources of new technology,” said Dr Elaine Stead, the Commercial Development Manager for Health Sciences at ARI, after attending her third BIO.

“Australia’s position is growing stronger at BIO,” he said. “This year large livestock companies approached us for meetings – companies, who had not engaged with us before.”



First-timers at the conference also reported new leads and opportunities, and found that BIO complemented other international conferences in their field.

“Every year we find it easier to get in touch with the big pharmaceutical and big biotechnology companies - and meet the key people. We’re becoming more proficient.”

**BIO 2007 will be held in Boston, Massachusetts from 6th – 9th May. For information visit [www.bio2007.org](http://www.bio2007.org)**

## South Australian bioscience – five years on

In June 2006, Bio Innovation SA reached the halfway point in its 10-year strategic vision - but with well over half its long-term goals for the local industry already met.

Bio Innovation SA was formed in 2001 by the South Australian Government to facilitate the growth of the local bioscience industry.

Since then, the number of local biotech companies has doubled. There are now more than 70 biotech companies in South Australia, employing almost 1000 people, generating more than \$175 million in revenue and raising almost \$95 million in private equity.

“The bioscience industry in South Australia has come a long way in the past five years,” Bio Innovation SA’s CEO Dr Jurgen Michaelis said.

“There is a thriving stable of companies based here making major inroads into global markets and we are constantly upgrading our infrastructure to facilitate the industry’s growth.

The Thebarton Precinct is the hub of the industry, where 90 high tech (including biotech) companies are co-located, employing 250 staff. The State Government is expanding the site by 4.9 ha, and will open a dedicated business incubator for early stage companies late next year. The building will provide state-of-the-art facilities for close to 100 staff.

Dr Michaelis said Bio Innovation SA had received a lot of interest from interstate biotechnology communities on what has been achieved in South Australia.

“There is intense competition among other states in Australia to attract the eye of global companies looking to invest in commercially sound science. South Australia has comparative advantages that we must continue to exploit and promote,” Dr Michaelis said.

Adelaide Facilities

## South Australian facilities - MAbSA

Monoclonal Antibodies South Australia (MAbSA) Technologies is the only facility of its kind in South Australia.



A joint venture between the University of Adelaide and the Institute of Medical and Veterinary Science (IMVS), "MAbSA" offers a "one-stop shop" for monoclonal antibody services: from the design of an appropriate immunogen to production of large scale purified antibodies for use in immunodiagnosics.

"Our antibodies are used for a number of purposes, including basic research, medical diagnostics – the identification of disease – and in food and agricultural research," said Dr Alfio Comis, the Managing Scientist of MAbSA.

"We are one of the few Australian commercial operators in our field. We are currently working with companies, hospitals and researchers throughout South Australia, and our business is expanding interstate, as well as overseas."

Monoclonal antibodies are highly specific reagents – they are designed to bind only to a specific region on the protein of interest to the researcher. This gives them the edge over polyclonal antibodies, which can attach themselves to different parts of the same protein and cross-react with other proteins.

"When an antibody is needed for a standardised test that needs to be very specific or needs to be repeated at different times and by different laboratories, monoclonal antibodies give both specificity as well as reproducible quantitation of results," said Dr Comis.

"We can design antibodies for specific purposes and produce them ourselves or provide the relevant cell lines for clients to grow them and produce the appropriate antibodies in their own laboratories."

For a number of years, the University of Adelaide and the IMVS have provided some of these services for their own researchers. MAbSA now combines the resources, and the many years of experience, of the two institutions to improve and expand the services offered to other researchers interstate and overseas, as well as commercial research companies.

Dr Comis himself has been an immunochemist for 22 years. He has held a number of senior academic and commercial research positions nationally and internationally, including a recent Associate Professorship at Cornell University in the USA.

As a scientist, his aim is to work closely with scientists needing monoclonal antibodies in their own research and helping solving their problems by tailoring the appropriate immunological reagents required.

"Our advantage, as a company based in Australia is that we can interact directly with the researchers. Scientists prefer to be directly involved in the production and testing of their own antibodies. When companies based overseas are used, it is logistically hard to have such an input."

"Our services are also more cost-effective and flexible. We involve our clients in all stages of the production process and we can accommodate their own resources, expertise and requirements to do some of the work themselves in order to reduce costs."

**For more information about MAbSA Technologies' services contact Alfio Comis on 08 8303 5262 or email [alfio.comis@adelaide.edu.au](mailto:alfio.comis@adelaide.edu.au)**

## ABIC 2006 Unlocking the potential of agricultural biotechnology

The Agricultural Biotechnology International Conference (ABIC), the major global conference for agricultural biotechnology will be held in the Southern Hemisphere for the first time from 6 – 9 August 2006.

Hosted in Melbourne by AusBiotech Ltd, ABIC 2006 will bring together leading international researchers in the AgBio sector

with industry partners and investors. The theme for ABIC 2006 will be "unlocking the potential of agricultural biotechnology", with the focus on both innovation and the commercialisation.

A South Australian exhibit is being coordinated by the Science, Technology & Innovation Directorate with the support of Bio Innovation SA, and will feature SARDI's Plant Research Centre, the Australian Centre for Plant Functional Genomics, the University of Adelaide, CSIRO Plant Industry, the Australian Wine Research Institute and the Australian Genome Research Facility.

**For further information on the ABIC Conference, visit [www.abic2006.org](http://www.abic2006.org)**

## Flinders launches IP program for small and medium sized enterprises



Dr John Turner of Flinders Technologies with PIP Program participant Garry Thompson of Garon Plastics and Tom Hubbard from the SA Centre for Innovation.

Flinders Technologies Pty Ltd – the technology commercialisation company of Flinders University - has launched the “Profit from IP Program” for small and medium sized enterprises.

Known as the ‘PIP’ Program, it draws on Flinders Technologies’ successful track record in commercialising IP assets internationally over two decades.

“The PIP Program is designed to complement and not compete with services provided by SMEs’ accountants, legal and business advisors,” said Dr John Turner, Managing Director of Flinders Technologies.

“The PIP Program fits in with the SA Centre for Innovation, Bio Innovation SA, AusIndustry, Austrade and other government agencies assisting with innovation and access to export markets.”

Many SMEs do not have the in-house resources to identify IP opportunities or to develop and implement commercialisation strategies to enable them to profit and grow.

The PIP Program is designed to meet the needs of SMEs by providing confidential disclosure agreements; assisting in the identification and protection of IP assets; devising IP commercialisation strategies for world markets; offering appraisals; and providing services on a low risk, low cost basis.

Flinders Technologies does not charge up front fees: its returns are obtained from successful commercialisation. “This minimises the risk for SMEs while optimising the potential for profit,” said Dr Turner.

“The PIP Program can also help companies gain private and government funds as well as R&D support, in particular, at Flinders University.”

**For more information about the PIP Program contact Mrs Deb White: [Deb.White@flinderstech.com](mailto:Deb.White@flinderstech.com) visit [www.flinderstech.com/SME/index.php](http://www.flinderstech.com/SME/index.php) or tel: (+618) 8201 7788.**

## ACPFPG delivers return on investment to South Australia

After three years of operation, the Australian Centre for Plant Functional Genomics (ACPFPG) has proved itself to be a sound investment for South Australia.

An international panel recently reviewing the operations of the ACPFG stated that “it is on track to become one of the best research centres in the world for cereal genomics”.

Through the South Australian Government’s support of \$12 million, the ACPFG has leveraged an additional \$38 million into South Australia over the past three years - an additional \$3.17 in funding from outside of the State for every dollar of South Australian Government investment.

The private company was established in 2003, and is funded to develop abiotic stress tolerance (drought, frost and nutrient deficiency) in wheat and barley.

“The ACPFG has developed world class infrastructure and assembled one of the best teams of cereal genetic researchers in the world,” said Mr Michael Gilbert, General Manager of the ACPFG.



The Board of the ACPFG (L-R): Mr Michael Gilbert, Prof Peter Langridge, Prof Vicki Sara, Mr Nick Begakis (Chair), Ms Maggie Dowling, Mr Simon Drilling and Prof Geoff Fincher

“The company was established to develop and commercialise intellectual property - our researchers have published 127 scientific papers in international journals over the past three years, and we’ve filed twelve patent applications.”

Over 100 people are now located at the ACPFG’s principle node at the Waite Precinct, 10 minutes from the Adelaide CBD.

**For further information on the ACPFG, visit [www.acpfg.com.au](http://www.acpfg.com.au)**

## Biotech careers on show

South Australia's future bioscientists and those seeking a new career challenge attended the 2006 AusBiotech Careers Spectacular at Adelaide's Observatory Function Centre in May.



Chief Executive Officer of AusBiotech, Dr Anna Lavelle presents Adam Palmer with his Student Excellence Award

Featuring a panel discussion and exhibits from a number of the State's biotechnology success stories, the event provided a unique opportunity for over 180 attendees considering their employment options.

Dr Anne Collins, Chair of the South Australian Chapter of AusBiotech said that the event was an important feature of the industry's calendar.

"The Careers Spectacular gives students and postgraduates the opportunity to meet a diverse range of industry representatives and to gain an insight on how to succeed in the industry," Dr Collins said.

Professor Mark Tester, Research Fellow at the Australian Centre for Plant Functional Genomics and keynote speaker at the event gave students an insight into what attributes he thinks are important for potential employees in the biotechnology sector.

"Be passionate and engaged with what you are doing, take opportunities when they arise... and always ask plenty of questions," Professor Tester said.

The event also saw the announcement of the AusBiotech Student Excellence Award for 2006. Adam Palmer from The University of Adelaide was awarded the SA State prize with his Honours Thesis entitled "Theoretical and experimental investigation of transcriptional interference between the pR and pRE promoters of phage lambda". Winners from each State will be flown to Sydney to attend the AusBiotech National Conference in November.

**For more information on AusBiotech events, visit [www.ausbiotech.org](http://www.ausbiotech.org)**

## People on the move

- Terry Evans, former Chair of the Attorney-General's Prudential Management Group has joined Minter Ellison as Special Counsel.
- Dr Anne Collins has taken the position of Client Services Manager at BresaGen Pty Ltd.
- The University of Adelaide's Mr Andrew Bartlett has been appointed Manager of the Thebarton Precinct.
- Mr Greg Hall, formerly of Bionomics has joined the Bio Innovation SA team as Technical Manager, assisting with the Thebarton Bioscience Precinct project.
- Ms Allison Bowman has been appointed Industry Development Officer with the South Australian Chapter of AusBiotech, Australia's biotechnology industry association.
- Former bioscience business consultant Dr Tim Kaethner has been appointed Chief Operations Officer at the ARC Plant Energy Biology, based in Crawley, Western Australia. Tim played an important part in the development of Bio Innovation SA and the formation of its initial strategy in 2000.
- Dr Dan Johnson, Business Development Manager at Bio Innovation SA, has left to take up the newly created position of Business Development Manager at The Australian Wine Research Institute (AWRI).





## Coming events

### World Congress on Industrial Biotechnology and Bioprocessing

11-14 July 2006

Toronto, Canada

[www.bio.org/worldcongress](http://www.bio.org/worldcongress)

### Australian Biotechnology Summit

26-27 July 2006

Sydney, Australia

[www.acevents.com.au/bio2006](http://www.acevents.com.au/bio2006)

### ABIC 2006: AgBiotech goes Australia

6-9 August 2006

Melbourne, Australia

[www.abic2006.org](http://www.abic2006.org)

### 11th International Congress of Human Genetics

6-10 August 2006

Brisbane, Australia

[www.ichg2006.com](http://www.ichg2006.com)

### 8th International Congress of Plant Molecular Biology

Adelaide, Australia

20-25 August 2006

[www.sallyjayconferences.com.au/ispmb2006/invitation.htm](http://www.sallyjayconferences.com.au/ispmb2006/invitation.htm)

### BIO Japan 2006

12-15 September 2006

Osaka, Japan

[expo.nikkeibp.co.jp/biojapan/2006/eng](http://expo.nikkeibp.co.jp/biojapan/2006/eng)

### AVCAL Conference 2006

26th & 27th September

Cairns, Australia

[www.avcal.com.au](http://www.avcal.com.au)

### Bio Investor Forum 2006

18-19 October 2006

San Francisco, USA

[www.investorforum.bio.org](http://www.investorforum.bio.org)

Communications consultant  
Sharon Mascall  
Making Sense Communications

Whilst every effort is made to ensure accuracy of the information contained in the newsletter at the time of printing, Bio Innovation SA, its officers, staff and agents accept no liability for any reliance placed on it. All information contained in this newsletter is copyright, Bio Innovation SA, 2005. All rights reserved. Apart from fair dealing permitted by the Copyright Act, 1968, no permission is given to reproduce this newsletter in any form.

## IN BRIEF

### GroPep considers restructure

GroPep Limited plans to examine the divestment of its biopharmaceutical development division – either through a spin-out or a trade sale – in order to focus on expanding its cell culture business.

The move is a recommendation arising from a review of the company's operating and corporate structure, recently completed by Ernst & Young.

**For further information, visit [www.gropep.com](http://www.gropep.com)**

### New facilities for SafetyMed

Safety Medical Products Ltd (SafetyMed) has opened its warehouse, distribution and testing facility at Salisbury Plain, South Australia after six months of operation as a public company.

SafetyMed's Securetouch single-use syringe retracts within its own sleeve cartridge, reducing the risk of needle stick injury.

In April last year, SafetyMed entered into an agreement with US-based medical product distributor Exelint International Co. for the manufacture of the Securetouch syringe in Korea, and exclusive sale and distribution through the US, Japan, Germany and the United Kingdom.

**For more information on SafetyMed, visit [www.safetymed.com.au](http://www.safetymed.com.au)**

### State award for University of Adelaide team

Researchers from the University of Adelaide have been awarded the South Australian Prize for most outstanding technology project at the recent Commercialisation Expo held in Melbourne.

The University's commercialisation arm, Adelaide Research and Innovation (ARI) submitted the technology on behalf of its developers - Dr Steven Polyak, Professor John Wallace, Dr Grant Booker and Mr Cvetan Stojkoski of the University of Adelaide's School of Molecular and Biomedical Sciences.

The technology uses an enzyme named Biotin Protein Ligase (BPL) as a target for the development of anti-infective agents such as anti-bacterials, anti-fungals and anti-parasitic agents.

The project was also shortlisted for the major award, the Peter Doherty Prize for Innovation.

More than 100 projects were submitted to the competition from across Australia.

### Save the date

Adelaide will host the inaugural AusBiotech / Bio Innovation SA National Business Development Conference from the 1st - 2nd March, 2007. This internationally focused event will address the specific needs of business development managers, commercialisation executives and licensing lawyers.

**Further details will be posted on the websites of Bio Innovation SA ([www.bioinnovationsa.com.au](http://www.bioinnovationsa.com.au)) and (AusBiotech [www.ausbiotech.org](http://www.ausbiotech.org))**

### Sponsorship opportunities

Bio Innovation SA has a number of sponsorship opportunities available for companies interested in targeting the South Australian bioscience community.

**For further information, contact Natasha Crichton, Bio Innovation SA's Industry Relations Manager on Ph. (+618) 8217 6400.**